Properties of poly(lactic-co-glycolic acid) nanospheres containing protease inhibitors: camostat mesilate and nafamostat mesilate.
Poly(lactic-co-glycolic acid) (PLGA) nanospheres containing protease inhibitors, camostat mesilate (CM) and nafamostat mesilate (NM), were prepared by the emulsion solvent diffusion methods in water or in oil, and the w/o/w emulsion solvent evaporation method. The average diameter of PLGA nanospheres prepared in the water system were about 150-300 nm, whereas those prepared in the oil system were 500-600 nm. Among the three methods, these drugs were the most efficiently encapsulated up to 60-70% in PLGA nanospheres in the oil system. Other factors that may influence drug encapsulation efficiency and in vitro release such as drug load, molecular weight of polymer were also investigated. Both the CM- and NM-loaded nanospheres prepared in the water system immediately released about 85% of the drug upon dispersed in the release medium while the drug initial burst of nanospheres prepared by the emulsion solvent diffusion in oil method reduced to 30% and 60% for CM and NM, respectively. Poly(aspartic acid) (PAA), a complexing agent for cationic water soluble drugs, showed little effect on the encapsulation efficiency and release behavior for CM and NM. The DSC study and AFM pictures of nanospheres demonstrated that temperature-dependent drug release behavior was ascribable to the glass transition temperature of the polymer, which also affected the morphology of nanospheres upon dispersed in the release medium and influenced the drug release consequently.
Yin
Jiahui
J
Department of Pharmaceutics, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya 467-8603, Japan.
Noda
Yasuhiro
Y
Yotsuyanagi
Toshihisa
T
D001550:Benzamidines; D002626:Chemistry, Pharmaceutical; D004952:Esters; D016670:Gabexate / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000737:chemistry; D006146:Guanidines / Q000008:administration & dosage / Q000737:chemistry*; D019344:Lactic Acid / Q000737:chemistry*; D008970:Molecular Weight; D043942:Nanotubes / Q000737:chemistry*; D010316:Particle Size; D010455:Peptides / Q000737:chemistry; D011100:Polyglycolic Acid / Q000737:chemistry*; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011108:Polymers / Q000737:chemistry*; D011480:Protease Inhibitors / Q000008:administration & dosage / Q000737:chemistry*; D012995:Solubility
D001550:Benzamidines; D004952:Esters; D006146:Guanidines; D010455:Peptides; D011108:Polymers; D011480:Protease Inhibitors; C034532:camostat; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; C017645:polyaspartate; D019344:Lactic Acid; D016670:Gabexate; C032855:nafamostat